Ventyx Biosciences（股票代码：VTYX）今日盘前股价大幅上涨69.25%，创下近期新高。
消息面上，据《华尔街日报》等多家媒体报道，全球制药巨头礼来公司（Eli Lilly）正在就以超过10亿美元的价格收购Ventyx Biosciences进行深入谈判。此次收购旨在拓展礼来在免疫学领域的业务布局，Ventyx专注于研发治疗克罗恩病、类风湿性关节炎等炎症性疾病的药物。
市场分析认为，这笔交易将为礼来带来丰富的产品管线，包括治疗炎症性肠病和帕金森症的药物。Ventyx目前还有一种治疗肥胖相关心血管疾病的实验性药物处于中期开发阶段，进一步增强了其吸引力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.